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Introduction: The self-assembly of Aβ peptides into a range of conformationally heterogeneous amyloid states
represents a fundamental event in Alzheimer’s disease. Within these structures oligomeric intermediates are considered
to be particularly pathogenic. To test this hypothesis we have used a conformational targeting approach where particular
conformational states, such as oligomers or fibrils, are recognized in vivo by state-specific antibody fragments.
Results: We show that oligomer targeting with the KW1 antibody fragment, but not fibril targeting with the B10
antibody fragment, affects toxicity in Aβ-expressing Drosophila melanogaster. The effect of KW1 is observed to occur
selectively with flies expressing Aβ(1–40) and not with those expressing Aβ(1–42) or the arctic variant of Aβ(1–42) This
finding is consistent with the binding preference of KW1 for Aβ(1–40) oligomers that has been established in vitro.
Strikingly, and in contrast to the previously demonstrated in vitro ability of this antibody fragment to block oligomeric
toxicity in long-term potentiation measurements, KW1 promotes toxicity in the flies rather than preventing it. This result
shows the crucial importance of the environment in determining the influence of antibody binding on the nature and
consequences of the protein misfolding and aggregation.
Conclusions: While our data support to the pathological relevance of oligomers, they highlight the issues to be addressed
when developing inhibitory strategies that aim to neutralize these states by means of antagonistic binding agents.
Keywords: Conformational disease, Misfolding, Neurodegeneration, Prion, Protein aggregationIntroduction
Amyloid fibrils are filamentous polypeptide aggregates
characterizing a range of human diseases, including
systemic amyloidosis and a variety of neurodegenerative
conditions [1-4]. In Alzheimer’s disease they are formed
from β-amyloid (Aβ) peptide [5-8]. This peptide is able
to aggregate into a multitude of different assembly states
[2-4]. It also occurs in different chemical isoforms
[9-11], but oligomeric intermediates of fibril formation
are often reported to play a pivotal role in AD pathogenesis
[6-8,12,13]. Much of the evidence supporting this view has
come from in vitro toxicity measurements or structures* Correspondence: marcus.faendrich@uni-ulm.de
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unless otherwise stated.that were prepared inside the test tube or extracted from
its native sources by highly invasive biochemical methods
[6,8,12,14-16]. Oligomers have thus been suggested as
targets of therapeutic or inhibitory strategies ameliorating
AD, and oligomer binding ligands, including conform-
ational antibodies, were shown to antagonize their anti-
neuronal activity in various assay systems [17-21].
To probe for the presence and relevance of specific Aβ
states in vivo, we have carried out a conformational target-
ing study, introducing two biophysically well-characterised
conformation-specific Aβ antibody fragments into a
Drosophila model of Aβ toxicity. Fly models are well
defined model systems and gave important insights into
the toxicity of Aβ and other polypeptide chains [22-28].
For our study we used flies expressing the 40 and 42
amino acid isoforms Aβ(1-40) and Aβ(1-42) and the
disease-associated E22G mutant of Aβ(1–42), termedLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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were generated previously through a biotechnological
approach. That is, they were phage display selected based
on their ability to discriminate between different conform-
ational states of Aβ from a fully synthetic library of cam-
elid heavy chain antibody fragments [17,29].
These monoclonal antibody fragments introduced into
the flies are termed KW1 and B10 (Figure 1A,B) [29,30].
KW1 binds oligomers of Aβ(1–40), while fibrils and disag-
gregated, that is largely monomeric, Aβ(1–40) peptide, or
oligomers of the more aggregation-prone Aβ(1-42) pep-
tide are not specifically recognized [14]. Bivalent KW1
binds to Aβ(1–40) oligomers with an apparent dissoci-
ation constant (aKD) of 43.5 nM and antagonizes oligomer
toxicity in long term potentiation (LTP) electrophysiology
experiments [14]. B10, by contrast, recognizes Aβ(1–40)
fibrils (aKD = 7 nM, determined for bivalent B10), but no
oligomers or disaggregated peptide [31,32]. B10 is lessFigure 1 B10 or KW1 do not noticeably affect the fly phenotype whe
structures of B10 (A) and KW1 (B), according to protein data base entries 3
that define the antigen binding sites, are coloured in blue (CDR1), red (CDR
constructs. The elav promoter drives the neuron-specific expression of Gal4
B10 through binding of an upstream acting sequence (UAS). (D, E) Reverse
and abdomen) homogenates from different fly lines probed for transcriptio
serves as a loading control. (F, G) WB shows a strong myc-positive band in
serves as a loading control. (H-J) Phenotypic comparison of B10 (red), KW1
standard deviation from three independent experiments using 15 flies each
eyes. Scale bars represent 20 μm.selective than KW1 and binds fibrils formed from a broad
range of polypeptide chains, including those of Aβ(1–40)
and Aβ(1-42) [30-34].
These properties, combined with the ability to pro-
mote the formation of either protofibrillar (B10) or
non-fibrillar aggregates (KW1) of Aβ [29,30,35], and to
bind to their corresponding conformers in human tis-
sue samples [29,30,32], enable B10 and KW1 to be used
to probe in a precise and well-defined manner how the
binding of particular Aβ conformers in a Drosophila
model of Aβ toxicity affects its self-assembly and con-
sequent neurodegeneration in vivo. By correlating these
observations with parallel studies of the effects of these
antibody fragments on the formation of cytotoxic ag-
gregates in vitro, we are able to rationalise their ability
(or lack of ability) to modulate the neurotoxicity of
each Aβ isoform in vivo on the basis of their conform-
ational selectivity.n expressed without Aβ. (A, B) Ribbon diagrams of the crystal
LN9 and 3TPK [29,31]. The complementary determining regions (CDRs),
2) and yellow (CDR3). (C) Schematic representation of the expression
protein, which subsequently induces the neuronal expression of KW1/
transcription polymerase chain reaction with head and body (thorax
n of B10 (D) or KW1 mRNA (E). Constitutively transcribed rp49 mRNA
B10 (F) and KW1 flies (G) at ~17 kDa molecular weight. Actin staining
(blue) and WT flies (black). (H) Locomotive assay. Error bars present
. (I) Viability assay. (J) Scanning electron microscopy images of the
Table 1 Median survival time of the fly lines
Expressed Aβ variant Expressed antibody fragment
None B10 KW1
None 43 ± 0.1 43 ± 0.2 42 ± 1.1
Aβ(1–42)arc 7 ± 0.1 6 ± 0.3 7 ± 0.2
Aβ(1–42) 32 ± 0.3 31 ± 0.6 32 ± 0.3
Aβ(1–40) (line Aβ40) 43 ± 0.6 41 ± 0.9 28 ± 1.1
Aβ(1–40) (line Aβ40-51D) 42 ± 1.1 - 36 ± 0.8
Aβ(1–40) (line Aβ40-29.1) 39 ± 0.8 - 39 ± 0.4
Values are given in days. Original data are shown in Figures 1 and 2 and
Additional file 1: Figure S4. Errors represent standard error of mean.
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Preparation of different Aβ conformers
The Aβ(1–40) peptide was recombinantly expressed in
house [36], while the Aβ(1–42) and Aβ(1–42)arc pep-
tides were obtained from chemical synthesis (Dr. Sven
Rothemund, University Leipzig, Germany). The purity
was > 96%, based on reverse phase high performance li-
quid chromatography. Fibrils were formed in vitro by in-
cubation of pure peptide at 1 mg/ml concentration in
50 mM sodium borate buffer, pH 9.0, for 5 days at room
temperature. Oligomers were prepared by dissolving pure
peptide at 2.5 mg/ml concentration in 100% 1,1,1,3,3,3-
hexafluoro-2-propanol [37]. After incubation for 15 min
at room temperature, the solution was diluted 10-fold
with H2O and further incubated for 15 min. Large aggre-
gates were then removed by spinning down the sample at
14,000 × g for 15 min. The supernatant containing the
oligomers was used for further analysis.
Generation of B10 or KW1 transgenic flies
The coding sequences for KW1 and B10 were obtained
by chemical synthesis (GeneArt), codon optimized for
Drosophila melanogaster. The genes were cloned into
the Gal4-responsive pUAST/attB expression vector (kind
gift of Konrad Basler; [38] and flanked by a 5′-SSP
sequence from Drosophila necrotic gene [39] and a 3′-
myc-tag (Additional file 1: Figure S1A). B10 and KW1
transgenic flies were commercially generated by PhiC31
integrase-mediated transgenesis using the attP landing
line zh-51D (Best Gene Inc.). Through polymerase chain
reaction of the genomic DNA from the two initial fly
lines +/+;B10/CyO;+/+and +/+;KW1/CyO;+/+we con-
firmed the presence of the KW1/B10 constructs within
the genomic DNA. B10 or KW1-expressing flies were
obtained through further crossing of these flies with the
Gal4-elavc155 pan-neuronal driver strain (Bloomington).
The Gal4-UAS system involves an upstream activating
sequence (UAS) element that activates the transcription
of KW1 or B10 when bound by Gal4 protein [40]. Gal4
expression, in turn, is controlled by the pan-neuronal
elavc155 promoter, which induces a neuron-specific ex-
pression pattern of Gal4 protein along with KW1 or
B10. The resulting strains are referred to in the text as
B10 or KW1 flies.
To co-express B10 or KW1 with Aβ, we crossed the
commercially obtained +/+;B10/CyO;+/+and +/+;KW1/
CyO;+/+lines with flies transgenic for Aβ(1–40), Aβ(1–42)
or Aβ(1–42)arc that had not previously been crossed with
the Gal4-elavc155 driver strain. This initial cross resulted in
the three initial B10 and Aβ double-transgenic strains +/+;
B10/CyO;Aβ(1–40)/TM6B, +/+;B10/CyO;Aβ(1–42)/TM6B
and +/+;B10/CyO;Aβ(1–42)arc/TM6B as well as the
three KW1 and Aβ double-transgenic strains +/+;KW1/
CyO;Aβ(1–40)/TM6B, +/+;KW1/CyO;Aβ(1–42)/TM6Band +/+;KW1/CyO;Aβ(1–42)arc/TM6B. Through a se-
cond cross of these flies with the Gal4-elavc155 strain,
we induced the expression of the transgenic proteins.
The resulting fly lines are referred to within the main
text as B10;Aβ40, B10;Aβ42, B10;Aβ42arc, KW1;Aβ40,
KW1;Aβ42 and KW1;Aβ42arc flies. They neuronally
express the gal4 gene, which encodes the yeast tran-
scription activator Gal4. Gal4 protein binds to the UAS
element, which activates the neuron-specific transcrip-
tion of Aβ, KW1 or B10.
In addition, we generated two further fly lines that were
co-expressing Aβ(1–40) and KW1. These lines were ob-
tained by crossing +/+;KW1/CyO;+/+flies with the Gal4-
elavc155 strain to obtain elav/elav;KW1/CyO;+/+flies. The
resulting animals were then crossed with the Aβ(1–40)
peptide expressing lines Aβ(1–40)-29.1, which behaves
identically to Aβ40 flies [22], and Aβ(1–40)-51D [41] flies
to generate the lines KW1;Aβ40-29.1 and KW1;Aβ40-
51D. The respective control lines (no KW1 expression)
were obtained by crossing Aβ(1–40)-29.1 and Aβ(1–40)-
51D flies with the Gal4-elavc155 strain to generate the
Aβ(1–40) expressing lines Aβ40-29.1 and Aβ40-51D. All
crosses were carried out at 25°C on standard Drosophila
food with dried yeast [42].
Survival assay
Ten groups of ten flies, were incubated at 29°C in 4-inch
glass vials (100 flies in total). The animals were kept on
standard food with dried yeast, and the food was replen-
ished every 2 days. The number of living flies was counted
every 2–3 days, and the resulting survival curves were eva-
luated with the Kaplan-Meier method that is implemented
within the Sigma Plot11 software (Systat Software Inc). Dif-
ferences between the genotypes were assessed by using the
log-rank test (Sigma Plot11). All survival times quoted in
the text and in Table 1 represent median values ± standard
error of mean.
Negative geotaxis assay
A negative-geotaxis assay was used to determine the
locomotor ability of the flies. A total of 15 flies (ntotal)
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the bottom. After 45 seconds, the number of flies that
had reaching the top of the pipette (ntop), as defined by
the 25 ml-mark, was determined. The number of flies
remaining at the bottom (nbottom) was defined by the
2 ml-mark. From these numbers the mobility index was
calculated according to the equation (ntotal + ntop − nbot-
tom)/2 ⋅ ntotal. This measurement was repeated three
times with independent groups of flies, consisting of 15
animals each. Climbing index values quoted in the text
represent mean values from the three independent mea-
surements ± standard error of mean.
Scanning electron microscopy analysis of the eye
morphology
Ten 1-day old adult animals were collected from each an-
alyzed fly line, anesthetized with carbon dioxide and fixed
over night in 500 μl of a 100 mM sodium cacodylate solu-
tion (pH 7.3) containing 2.5% glutaraldehyde (4°C). The
fixative was removed by washing the flies 5 times for
5 min in 500 μl sodium cacodylate buffer without glutaral-
dehyde, followed by a series of 5 dehydration steps (500 μl
each), where the ethanol concentration was progressively
raised from 10 to 100%. The organic solvent was removed
by critical point drying in a BAL-TEC CPD 030 Critical
Point Dryer. All samples were evacuated and sputtered
with gold (layer thickness 20 nm) in a BAL-TEC SCD 005
Sputter Coater. The final analysis was done using a
scanning electron microscope Zeiss (LEO) 1450 VP at
8 kV acceleration voltage and pictures were taken at
200 × magnification.
Immunohistochemistry
Whole brains were dissected from adult fly heads and
transferred into 500 μl ice cold PBS. For fixation the
brains were then transferred into 4% (w/v) paraformal-
dehyde in PBS for 1 h at room temperature. Afterwards
the fixative was removed and the brains were blocked
with 5% normal goat serum in PBS (15 min). The brains
were then infiltrated for 2 h with 6E10 (Aβ1-16, mono-
clonal, mouse, Covance, 1:500), anti-elav (monoclonal,
rat, DHSB, 1:50) or anti-myc antibody (ab9106, poly-
clonal, rabbit, Abcam, 1:500). All antibodies were diluted
in PBT (PBS + 0.05% TritonX-100). Unbound antibodies
were removed with three washing steps (500 μl PBT,
10 min each) followed by a 1 h incubation with donkey
anti-mouse IgG Alexa Fluor®555, donkey anti-rabbit IgG
Alexa Fluor®488 (Molecular Probes, 1:200) or anti-rat
IgG TRITC (JacksonImmuno Research, 1:200) as appro-
priate. To remove unbound secondary antibodies, the
brains were washed three times with 500 μl PBT, before
they were incubated 10 min with 500 μl Hoechst 33342
dye (1 μg/ml in PBS) to stain the nuclei. Finally, the
brains were mounted using VECTASHIELD® mountingmedium (Vector laboratory). All steps were performed
at room temperature, unless indicated otherwise. All sam-
ples were analysed using a Nikon ECLIPSE TE2000-E
confocal laser-scanning microscope. Pictures were taken
at a magnification of 60 ×.
Protein extraction from flies
Flies were anesthetized, shock frozen on dry ice and de-
capitated. Depending on whether the proteins samples
were supposed to be used for denaturing sodium dode-
cylsulphate (SDS) polyacrylamide gel electrophoresis
(PAGE) or native PAGE we then used slightly different
extraction methods. Denaturing SDS PAGE analysis: we
homogenized 20 fly heads or 5 fly bodies in 20 μl
phosphate-buffered saline (PBS, 137 mM NaCl; 2.7 mM
KCl; 8 mM Na2HPO4; 2 mM KH2PO4; pH 7.4), which was
supplemented with 1% SDS and the complete protease in-
hibitor cocktail (Roche Applied Science). Homogenization
was performed manually by using a plastic pistil. The ho-
mogenates were sonicated for 8 min and spun down for
7 sec, before the supernatants were collected. The protein
concentrations in these samples were determined with the
DC Protein Assay (Biorad), and the protein concentration
was adjusted in the various samples to ensure equal load-
ing on the gel. All samples were then mixed with 5 μl 4×
NuPAGE® sample buffer (Invitrogen) and heated for
10 min at 95°C. The samples were then separated on
NuPAGE® 4–12% Bis-Tris gradient gels with NuPAGE®
MES SDS running buffer (Invitrogen).
For native PAGE analysis, we manually homogenized
20 fly heads in 20 μl PBS, supplemented with the
cOmplete protease inhibitor mix. This suspension was
sonicated for 8 min, spun down for 7 sec to remove in-
soluble material, and the supernatant was mixed with 5
μl of 4× NativePAGE® sample buffer (Invitrogen). These
electrophoresis samples were not boiled before they
were separated on NativePAGE® 4-16% Bis-Tris gradient
gels with NativePAGE® running buffer (Invitrogen). The
further readout of the results was performed with WB
analysis, if required.
RNA extraction and polymerase chain reaction
To check the transcription of the KW1 and B10 genes in
the animals, we used a three step protocol: RNA extrac-
tion from the flies, conversion of RNA into cDNA and
analysis of the cDNA to confirm the coding sequences of
B10 or KW1.
RNA isolation was based on TRIzol® reagent (Invitrogen).
In brief, flies were anesthetized and shock frozen on dry
ice in Eppendorf tubes. Flies were decapitated by shaking
the Eppendorf tube on dry ice to break the neck of the
flies. The heads were manually separated from the
remaining bodies. 15–20 heads or 5 bodies were ho-
mogenized in 150 μl TRIzol® by using a plastic pistil.
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thoroughly vortexed and the organic and aqueous
phases were separated by centrifugation (13,000 × g,
15 min, 4°C). The aqueous phase was transferred into a
new tube and all nucleic acids were precipitated by
using 75 μl pure isopropanol, followed by centrifuga-
tion at 13,000 × g for 15 min at 4°C. The pellet was
briefly washed with 150 μl of 70% ethanol, air dried and
re-dissolved in 20 μl RNAse free water.
As a next step, 1 μg of the purified RNA was trans-
ferred into a fresh tube and the residual genomic DNA
was removed by enzymatic digestion with 1 unit DNAse
for 30 min at room temperature. All of the resulting
pure RNA was then used for reverse transcription poly-
merase chain reaction to generate cDNA (RevertAid™
First Strand cDNA Synthesis Kit, Fermentas), which was
used according to the manufacturer’s instructions.
Finally, 1 μl of the resulting cDNA were subjected to
polymerase chain reaction, which consisted of an initial
denaturation step [5 min at 95°C] followed by 28 cycles
each of which consisted of 30 sec at 95°C [denaturation],
30 sec at 57°C [primer annealing] and 30 sec at 72°C
[elongation]. At the end of these cycles we applied a
final extension step of 5 min at 72°C. The polymerase
chain reaction products were separated on an agarose
gel and photographically imaged. Primers used to amp-
lify B10 and KW1 cDNA were designed based on the
coding sequences of KW1 and B10 genes. Primers used
to amplify Aβ cDNA were designed based on the coding
sequences of Aβ transgene. Amplified rp49 cDNA
served as a loading control. See Additional file 1: Table
S1 for primers.
Immunoprecipitation
Magnetic protein A coupled beads (Invitrogen) were
pretreated by blocking 10 μl of the resuspended beads in
100 μl 2% BSA in PBS + 0.025% TritonX-100. After incu-
bation for 15 min, the beads were washed twice in 100 μl
PBS + 0.025% TritonX-100 for 5 min. 3 μg of the dissolved
antibody (6E10) were added to 100 μl PBS +0.025%
TritonX-100 and incubated with the beads for 15 min to
allow coupling of the antibodies to the beads. After this
pre-treatment, 10 to 20 fly heads were homogenized with
a plastic pistil in 20 μl PBST containing the cOmplete pro-
tease inhibitor mix. The suspension was sonicated for
1 min, centrifuged for 7 sec and the supernatant was
transferred into a fresh tube. This solution was then di-
luted with 80 μl PBS + 0.025% TritonX-100, mixed with
the pre- treated beads and incubated for 20 min. The
beads were washed thrice with 100 μl PBS + 0.025%
TritonX-100 (5 min) and transferred into a fresh tube.
Specifically bound proteins were eluted from the beads
with 20 μl 50 mM glycine (pH 2.8) and incubation for
10 min. Afterwards the beads were boiled in 20 μl 1×NuPAGE® LDS Sample Buffer (Invitrogen) and applied
onto the gel to check for unspecifically bound proteins.
All steps were performed at room temperature, unless in-
dicated otherwise. The resulting fractions were analysed
using WB. Anti-myc antibody was used to detect the
expressed myc-tagged B10 antibody fragment, while 6E10
was used against Aβ.
To test for possible interactions between KW1 and Aβ
peptide, a modified protocol had to be used, because fly
KW1 (unlike fly B10) was found to directly bind to
protein A beads. Therefore, the bead pre-treatment
consisted only of the blocking of 10 μl resuspended
beads (in 100 μl 2% BSA, PBS, 0.025% TritonX-100),
incubation for 15 min and two washing steps as de-
scribed above. After this pre-treatment, 10 to 20 fly
heads were prepared as described above and mixed with
the pre-treated beads. The further steps were carried out
as described above. Anti-myc antibody was used to de-
tect the expressed myc-tagged KW1 antibody fragment
via WB, while 6E10 was used against Aβ. All steps were
carried out at room temperature.
Fluorescence spectroscopy
Thioflavin T (ThT) and 8-naphthalene-1-sulfonate (ANS)
spectra were recorded at room temperature using the LS
55 fluorescence spectrometer (Perkin Elmer). All spectra
represent averages of 5 scans. ThT fluorescence was ex-
cited at 450 nm and the emission spectrum was recorded
between 460 and 700 nm. All ThT spectra were recorded
with samples containing 15 μM ThT and 20 μM Aβ. ANS
emission spectra were measured from 380 to 700 nm,
whilst exciting at 374 nm. In this measurement samples
contained 200 mM ANS and 20 μM Aβ peptide.
Spot blot
1–20 μg from each Aβ peptide species were blotted onto
nitrocellulose membrane (GE Healthcare or Schleicher
and Schuell) using pore sizes of 0.1 μm or 0.45 μm. The
membrane was blocked for 1 h with 2% bovine serum al-
bumin (BSA) solution in TBST, which is Tris- buffered
saline (50 mM Tris, 200 mM NaCl, pH 7.4), containing
0.01% Tween 20. Equal loading was confirmed with Pon-
ceau red staining of unblocked control membranes.
Membranes were washed thrice in TBST for 5 min, be-
fore they were further incubated for 1 h with 4 μg/ml
B10AP or KW1AP in TBST. B10AP or KW1AP binding
was visualized with NBT/BCIP reagent (Pierce). All steps
were carried out at room temperature. Densitometric
quantifications of the scanned blots were carried out
with TotalLab 100 software.
Congo red (CR) absorption spectroscopy
CR absorption was measured at room temperature using
the Lambda 900 spectrometer (Perkin Elmer). The
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peptide. Absorbance spectra were recorded from 400 to
700 nm with 3 scans per spectrum. CR absorption spectra
of Aβ fibrils or buffer control always contained 50 mM
sodium borate buffer, pH 9.0, while Aβ oligomers or
controls were measured in 10% 1,1,1,3,3,3-hexafluoro-2-
propanol (HFIP).
Aggregation kinetics measurements
Aggregation kinetic measurments are based on time-
resolved ThT fluorescence measurements, carried out
online in a 96-well plate and by using a FLUOstar OP-
TIMA (BMG Labtech) plate reader (37°C). ThT fluores-
cence was recorded by using excitation and emission
wavelengths of 482 nm and 490 nm, respectively. Each
measurement cycle consisted of 30 min incubation
followed by orbital shaking at 100 rpm for 10 seconds
immediately before the measurement. Samples were pre-
pared by initially disaggregating Aβ(1–40) peptide as de-
scribed [43]. The disaggregated peptide was dissolved at
high concentration in 100% dimethyl sulphoxide (DMSO),
and the accurate Aβ concentration was determined by ab-
sorbance spectroscopy [44]. To that end we diluted 10 μl
of the DMSO-stock with 190 μl pure water and 800 μl of
7.5 M guanidine hydrochloride, 25 mM sodium phosphate
buffer, pH 6.5. The optical density at 280 nm was recorded
with a Helios γ UV–vis spectrophotometer, and the
concentration was derived based on a theoretic molar ex-
tinction coefficient of 1280 M−1 cm−1. From the DMSO
stock aliquots were diluted with buffer and other reagents
to yield the final sample. These samples contained always
a volume of 100 μl, 25 μM Aβ(1–40), 20 μM ThT, 50 mM
HEPES buffer (pH 7.4), 50 mM NaCl, a protease inhibitor
cocktail (Complete mini, Roche) (1×) and, where appro-
priate, 5 μM KW1. The DMSO concentration was always
less than 5%.
Transmission electron microscopy (TEM)
TEM specimens of Aβ oligomers and fibrils were pre-
pared by placing 5 μl of each sample solution onto a
Formvar/carbon copper grid (200 mesh, Plano) followed
by 1 min of incubation. The grid was washed by dipping
it subsequently into 3 droplets of water (~50 μl) and the
specimen were counterstained with 3 droplets (~50 μl)
of 2% (wt/vol) uranyl acetate. Samples were examined
using a Zeiss 900 electron microscope that was operated
at an acceleration voltage of 80 kV. Samples were im-
aged at a magnification of 30,000 × .
Long term potentiation (LTP) measurements
For measuring the influence of various Aβ species on
LTP isolated hippocampal slices (400 μm thickness) were
prepared from 4-months old C57/B16 mice as described
previously [45]. The slices were maintained in a pre-chamber containing 8 ml carbogen-gasified artificial
cerebrospinal fluid (ACSF, 124 mM NaCl, 25.6 mM
NaHCO3, 1.2 mM KH2PO4, 4.9 mM KCl, 2.5 mM CaCl2,
2 mM MgSO4, 10 mM glucose).
We prepared three different Aβ-containing samples by
incubation of 100 μM Aβ with or without 20 μM KW1
in 50 mM HEPES buffer (pH 7.4) and 50 mM NaCl for
5 days at 37°C without shaking. The sample incubated
without KW1 was divided into two parts. One was ap-
plied to the slice as it was, to the other one we added
KW1 15 min before addition to the slices. Sample solu-
tions containing 1 μM Aβ were applied to the slices in
the pre-chamber for 2 hours. The respective control so-
lution contained no Aβ. The slices were then transferred
into a submerge-type recording chamber and were
allowed to recover for at least 30 min before starting the
electrophysiological experiments. The recording cham-
ber was constantly perfused with ACFS at a rate of
2.5 ml/min at 32 ± 1°C.
Synaptic responses were elicited by stimulation of the
Schaffer collateral commission fibers in the stratum
radiatum (CA1 region) using lacquer-coated stainless
steel stimulating electrodes. Glass electrodes (filled with
ACSF, 1–4 MΩ) were placed in the apical dendritic layer
to record fEPSPs. The initial slope of the fEPSP was used
as a measure of this potential. The stimulus strength of
the test pulses was adjusted to 30% of the EPSP max-
imum. During baseline recording, single stimuli were ap-
plied every minute (0.0166 Hz) and were averaged every
5 min. Once a stable baseline had been established,
long-term potentiation was induced by applying 100
pulses at an interval of 10 ms and a width of the single
pulses of 0.2 ms (strong tetanus) three times at 10 min
intervals.
Protein structure representation
KW1 and B10 crystal structures were displayed as rib-
bon diagrams by using the program PyMOL (DeLano
Scientific). The structures have the following protein
database identification numbers: 3LN9 (B10) and 3TPK
(KW1) [29,31].
Recombinant expression of B10AP and KW1AP in E.coli
B10AP and KW1AP were recombinantly expressed in
E. coli and purified according to established procedures
[29,30].
Cultivation of SH-SY5Y and measurements of metabolic/
toxic activity
SH-SY5Y cells were grown in Dulbecco’s Modified Eagle
Medium (DMEM, PAA Laboratories) supplemented with
10% heat-inactivated fetal bovine serum and 2% Pen/
Strep (PAA Laboratories) at 37°C with 10% CO2. Cells
were seeded into 96-well plates at a density of 50 000
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37°C. After 24 h the medium was removed and fresh
medium was added together with the Aβ samples or
controls to be analyzed.
The Aβ samples were obtained by initially dissolving
disaggregated Aβ at high concentration in 100% DMSO.
The peptide was then quantified and diluted to a final
concentration of 100 μM into 50 mM HEPES buffer
pH 7.4, containing 50 mM NaCl. If applicable, the solu-
tion also contained 20 μM B10 or KW1, and it was incu-
bated for different periods of time at 37°C. After
incubation the Aβ-containing analytes were added to the
cells to reach a final concentration of 1 μM Aβ peptide.
The cells were then incubated for 24 h at 37°C with the
analytes before measuring the cellular effects with one of
two assays.
Cell metabolic activity was assessed with a FLUOstar
Omega 96-well plate reader (BMG LABTECH) by using
the Cell Proliferation Kit I (MTT, Roche) or LDH-
Cytotoxicity Assay Kit II (BioVision) according to the
manufacturer’s protocol. Statistical analyses were carried
out using the paired t-test implemented with Sigma-
Plot11 (Systat software).
Results
Oligomer and fibril targeting differentially affect Aβ
induced neurotoxicity in vivo
We transgenically expressed B10 or KW1 in Drosophila
melanogaster flies within the central nervous system using
the elavc115-Gal4 driver [22] (Figure 1C). An N-terminal
secretion signal peptide (SSP) ensures their insertion into
the secretory pathway, whereas an additional C-terminal
myc-tag was fused to aid their detection (Additional file 1:
Figure S1). Reverse transcription polymerase chain re-
action (Figure 1D,E) and anti-myc western blotting
(Figure 1F,G) of fly head extracts from Drosophila ex-
pressing B10 or KW1 alone under the control of the
elavc155Gal4 system confirmed that both proteins were
stably expressed in KW1 and B10 flies. The two proteins
relatively inert properties, as they do not discernibly affect
the fly phenotype when expressed in isolation, as deter-
mined by locomotive behaviour (Figure 1H), fly longevity
(Figure 1I, Table 1) or eye structure (Figure 1J). Western
blot shows only very little interactions between KW1 and
B10 and endogenous fly proteins (Additional file 1: Figure
S2). Expression of B10 and KW1 protein constructs in
Drosophila Schneider S2 cells demonstrates that fly cells
are able to express both antibody fragments as functional
proteins that fully reproduce the conformational selectiv-
ity (Additional file 1: Figure S3) that we previously estab-
lished for E.coli-derived proteins [29,30].
Flies were generated in which KW1 was co-expressed
together with either of the peptides Aβ(1-40), Aβ(1-42)
or the early onset AD-associated E22G mutant Aβ(1–42)arc to investigate KW1’s effects on Aβ neurotoxicity.
The resulting fly lines are termed KW1; Aβ40, KW1;
Aβ42 and KW1; Aβ42arc. Whilst expression of Aβ(1-40)
or KW1 alone do not cause significant neurotoxicity in
Drosophila (Figure 1H-J, Table 1), co-expression of
Aβ(1-40) with KW1 results in a significant 35% reduc-
tion in fly lifespan, compared to that of Aβ(1-40) ex-
pressing flies (from 43 ± 0.6 days to 28 ± 1.1 days;
Table 1). Analysis of the effects of KW1 expression in
two other Aβ(1–40) peptide-expressing lines (Aβ(1–40)-
29.1 and Aβ(1–40)-51D) shows that the magnitude of the
increase in toxicity associated with KW1 co-expression in
each case correlated with the concentration of Aβ(1-40)
(Figure 2D), as determined by western blot analysis of
head homogenates (Additional file 1: Figure S4). There-
fore, KW1 induces Aβ(1-40)-dependent neurotoxicity, al-
though it does not discernibly affect other phenotypic
properties, such as eye structure or climbing behaviour
(Additional file 1: Figure S5A-C). The effect of KW1 is
strikingly selective and co-expression with Aβ(1-42) and
Aβ(1-42)-arc does not cause any significant change in
lifespan compared to the expression of Aβ(1-42) or
Aβ(1-42)-arc alone (Additional file 1: Figure S5D-I).
While this selectivity fully agrees with in vitro data that
KW1 preferentially interacts with Aβ(1-40) oligomers
(Figure 3), it sharply contrast to results obtained upon co-
expression of B10 together with Aβ in Drosophila, where
we see no detectable phenotypic effects when com-
pared to the expression of any of the Aβ peptides
alone (Additional file 1: Figure S5). For all examined
properties we find B10;Aβ40, B10;Aβ42 and B10;Aβ42arc
flies to correspond to the respective lines Aβ40, Aβ42 and
Aβ42arc. Although B10 is able to bind to all three fibril
structures in vitro (Figure 3J) and although it perturbs fi-
bril formation in vitro [30,35] and promotes protofibril
formation at the expense of mature structures, fibril tar-
geting with B10 does not affect the neurotoxicity of any of
these peptides in vivo.
KW1 selectively affects Aβ(1–40) peptide and alters its
deposition in the brain
Aβ40 flies do not exhibit significant Aβ deposits by
20 days of age (Figure 4A,B), whereas co-expression of
KW1 results in their appearance in age-matched flies
(Figure 4B). KW1 partially co-localises with these foci
and pull down of KW1 from KW1;Aβ40 head homoge-
nates results in the co-immunoprecipitation (co-IP) of
Aβ(1-40) (Figure 4C). While these data imply that KW1
affects the structure of Aβ concomitantly with inducing
its toxicity, interactions must be rather transient in na-
ture as we see no complete co-localisation between the
two expression products. KW1 expression also does not
significantly increase the steady state levels of Aβ(1-40)
detected by western blotting of brain lysates of 3 or
Figure 2 KW1 expression reduces the viability of different Aβ(1–40) expressing fly lines. (A-C) Lifespan measurements of Aβ40 flies (filled)
and KW1;Aβ40 flies (unfilled) (A), Aβ40-51D flies (filled) and KW1;Aβ40-51D flies (unfilled) (B) and Aβ40-29.1 flies (filled) and KW1;Aβ40-29.1 flies
(unfilled) (C). (D) Fly viability versus Aβ concentration in the fly head. The fly viability (%) is given relative to fly lines without KW1 expression.
Symbols: Filled diamond: KW1 relative to WT. Unfilled square: KW1;Aβ40-29.1 relative to Ab40-29.1. Unfilled triangle: KW1;Aβ40-51D relative to
Aβ40-51D. Unfilled circle: KW1;Aβ40 relative to Aβ40. Data were fitted by linear regression (R = 0.86). For original values please refer to Table 1.
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marily alters the spatial distribution and/or assembly state
of Aβ(1–40) without dramatically changing its solubility.
Concerning B10, there was also no evidence that insuf-
ficient concentrations or a complete lack of interactions
might explain the absence of effects of B10 expression
on the flies. The ratio B10 to Aβ(1-42)-arc present in the
fly brain (1:3) (Additional file 1: Figure S6) exceeds that
at which B10 has been shown to be effective at sup-
pressing Aβ fibril formation in vitro (as low as 1:10)
[30]. Co-IP from fly head homogenates demonstrates that
the two proteins are able to interact with one another
(Additional file 1: Figure S4C), although there is only li-
mited co-localization of the two expression products in
B10;Aβ42arc flies (Additional file 1: Figure S4A, B).
KW1 induces non-fibrillar aggregates with synaptotoxic
activity
The finding that KW1 expression specifically affects Aβ(1-
40)-transgenic animals was highly surprising, given that it
had previously been shown to antagonize Aβ(1-40) oligo-
mer induced neurotoxicity (Figure 5A,B), as measured by
the ability of preformed oligomers of Aβ(1-40) to disrupt
synaptic plasticity and LTP in cultured murine brain slices
[29,37,46]. An obvious contrast between the fly model de-
scribed here, and previous in vitro work is that KW1 isproduced in the brain of the fly concomitantly with
Aβ(1-40) peptide and is present during fibril or oligo-
mer formation (Figure 5C). Indeed, if we remodel such
a situation in vitro by addition of KW1 to disaggregated
Aβ(1-40) we find a significantly perturbed fibrillation
pathway (Figure 5C). KW1 results in an extended lag
phase and the formation of non-fibrillar species at the ex-
pense of mature fibrils (Figure 5D,E), similar to previous
observations with dimeric KW1 [29]. Measured concen-
trations of KW1 (~1 μM) and Aβ(1–40) (~0.2 μM) in fly
head homogenates (Additional file 1: Figure S4) translate
into a 5:1 molar stoichiometry and are significantly larger
than the sub-stoichiometric 1:5 molar ratio of KW1 to Aβ,
which suffices to perturb Aβ(1–40) aggregation in vitro
(Figure 5D,E).
The non-fibrillar aggregates formed by KW1 co-
incubation with disaggregated Aβ(1–40) expose more sur-
face hydrophobicity, as measured by increased binding of
the dye 8-anilino-1-naphthalenesulfonic acid (ANS), than
the more fibrillar aggregates formed in the absence of
KW1 (Figure 5F). They also bind Thioflavin T (ThT), a
dye that interacts with ordered β-sheet rich aggregates,
more weakly than the more fibrillar species formed in the
absence of KW1 (Figure 5G).
As surface exposed hydrophobics and weak ThT binding
were previously described as a signature of toxic amyloid
Figure 3 B10 and KW1 binding to different Aβ structures. (A-B) TEM images of intermediates (A) and amyloid fibrils (B) of the different Aβ
variants as indicated. Scale bar represent 200 nm. Intermediates and fibrils are further characterized by interactions with Congo red (C, G), Thioflavin T
(ThT, D, H) and 8-anilinonaphthalene-1-sulfonate dyes (ANS, E, I). Measurements with fibrils were carried out in 50 mM sodium borate, pH 9.0.
Reactions with intermediates contained 10% HFIP in water as the base solution. (F) Spot blot data of alkaline phosphatase (AP) coupled KW1 binding
to intermediates. Densitometric quantifications and representative raw data stained with either Ponceau (loading control, white bars) or KW1AP
(black bars). Aβ(1–40) Ponceau and KW1AP signals have been set to 100%. Error bars show standard deviation (n = 2–3). (G-I) Congo red, ThT and ANS
binding of fibrils in 50 mM sodium borate buffer, pH 9.0. (J) Spot blot data of AP coupled B10 binding to fibrils. Densitometric quantifications and
representative raw data shown. All panels show the same colour coding: black: solution without Aβ; ochre: Aβ(1–40); turquoise: Aβ(1–42); green: Aβ(1–42)arc.
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whether or not the neurotoxic effects of expressing KW1
with Aβ(1-40) in vivo can be rationalised by the ability of
KW1 to promote the formation of hydrophobic non-
fibrillar Aβ(1–40) aggregates. We applied different
Aβ(1-40) preparations to the slice for 2 hours prior to
electrophysiology recordings. We found that a 2 hour
pre-incubation of the slices with 5-day old non-fibrillar
Aβ(1–40) aggregates formed in the presence of KW1,
prior to their addition to the culture, significantly in-
hibits LTP compared to untreated cultures (Figure 5H).
The synaptic potentiation measured at 225 min was
102% ± 9 field excitatory postsynaptic potential (fEPSP)
with KW1-induced Aβ(1–40) aggregates and 141% ± 10
fEPSP in the buffer treated control. No significant effect
on the establishment of LTP is observed, if slices are
pre-incubated for 2 hours with 5-day old Aβ(1–40)
fibrils formed in the absence of KW1 (Figure 5I) or ifKW1 was added to the fibrils after their formation but
prior to their addition to the slice cultures (Figure 5J).
We confirmed these effects for a human neuronal
system by adding these same Aβ(1-40)/KW1 prepara-
tions to human neuroblastoma (SH-SY5Y) cells and mea-
surement of their effects on neuronal metabolic activity
with the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazo-
lium bromide (MTT) assay. Co-incubation of Aβ(1-40)
with KW1 throughout the aggregation reaction generated
aggregates that modulate the activity SH-SY5Y cells and
induce a marked ~12% reduction of the MTT value
(Figure 6A), whereas those formed in the absence of KW1
or in the presence of B10 did not (Figure 6A). Notably,
the activity of Aβ(1-40) when co-incubated with KW1 in-
creased with the length of the incubation time prior to
their application to the cultured cells (from 1 to 5 days).
This observation is in full accord with the effect of
KW1 being to promote the progressive accumulation of
Figure 4 KW1 interacts with Aβ(1–40) in fly tissue samples. (A) Immunofluorescence microscopy image of the protocerebral lobe (PL) and
optical lobe (OL) regions of WT Drosophila brain stained with Hoechst 33342 to visualize cell nuclei. (B) IFM images of adult brains from 3-day
and 20-day old WT (top), Aβ40 (middle) and KW1;Aβ40 flies (bottom). Left column (blue): Hoechst 33342 staining. White boxes indicate the
regions enlarged in the following three columns. Second column (red): Aβ-staining with 6E10 antibody. Third column (green): anti-myc antibody
staining of myc-tagged B10 or KW1. Right column: overlay of the anti-myc and 6E10 signals. Arrows indicate signal co-localisation. Scale bars
represent 50 μm (A,B). (C) IP analysis of head homogenates from 20-day old KW1;Aβ40 and Aβ40 flies. Pull downs were performed against KW1.
Resulting fractions were analyzed with WB to detect either Aβ (6E10) or myc-tagged KW1 (anti-myc). Abbreviations: T, total sample before IP; S,
supernatant after incubation with beads; W, wash fraction; E, elution; B, beads after elution. (D) WB analysis with heads from 3-day and 20-day old
Aβ40 and KW1;Aβ40 flies. Samples were probed with 6E10 to detect Aβ peptide (black bars). Anti-actin staining serves as loading control (white bars).
All bars are normalised to the 3 days old Aβ40 sample (n = 2).
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Figure 5 Structural and biological effects of KW1 on Aβ(1–40) peptide in vitro. (A-C) Hypothetical models of KW1 activity that are
considered in this work; (A-B) KW1 antagonizes the toxic effect of oligomers. (C) KW1 modifies the Aβ assembly reaction. (D) Aggregation of
Aβ(1–40) monitored by time-dependent ThT fluorescence at 490 nm. Black: Aβ(1–40) alone; grey: Aβ co-incubated with KW1 (n = 5). Length of
the lag-phase: 5.6 ± 0.5 h (without KW1) and 24 ± 2.7 h (with KW1). (E-G) Structural comparison of Aβ fibrils, obtained by incubation of 100 μM
Aβ(1–40) in 50 mM HEPES buffer, pH 7.4, 50 mM NaCl for 5 days at 37°C, and of KW1-stabilized aggregates, obtained by co-incubation of 100 μM
Aβ(1–40) with 20 μM KW1 under the same conditions. (E) Negative stain TEM images. Different regions of the grid of KW1-induced aggregates
are shown. Scale bar represents 200 nm. (F) ANS and (G) ThT fluorescence spectra recorded with KW1-stabilized Aβ aggregates (grey) or Aβ fibrils
(black). Dashed spectra: dye without protein. (H) KW1-induced aggregates, obtained by co-incubation of Aβ(1–40) with KW1 for 5 days, potently
reduces the LTP response (p = 0.029, estimated with repeated-measures ANOVA). (I) LTP measurement with slices pre-treated with Aβ(1–40) fibrils,
obtained by a 5-day incubation of the pure peptide, shows no significant deviation from the buffer control. (J) Addition of KW1 to these fibrils
15 min prior to addition to the slice does not modify this result. Error bars (grey) represent standard error of the mean (n = 8-20).
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scale (Figure 6B). These effects of combinations of KW1
and Aβ(1–40) on neuronal metabolic activity were signifi-
cantly smaller than those observed following treatment
with Aβ(1–42) and Aβ(1–42)arc peptides (Figure 6D). In
line with other experimental paradigms reported here, the
activities of the latter were also not modifiable by KW1
and did not depend on the presence or absence of this
antibody fragment during aggregation.
While MTT does not directly monitor neuronal death
in these experiments, lactate dehydrogenase (LDH)
assay, which measures membrane disruption and thusreports more directly on cellular toxicity than MTT,
shows no significant effects of Aβ on SH-SY5Y cells
(Figure 6C), we find a striking correlation of the MTT-
effects and fly toxicity in vivo (Figure 6E). Therefore,
pure peptides are able to form species in vitro that cap-
ture activities associated with Aβ pathogenicity in vivo.
They further testify to the existence of different popula-
tions of Aβ assemblies inside the fly that differ in the
chemical structure of Aβ peptide, formation mechan-
ism and sensitivity towards modulation by KW1; that
is, there is no uniquely active Aβ structure but a collec-
tion of toxic Aβ structures in vitro and in vivo.
Figure 6 Effect of KW1 on the metabolic activity of Aβ-species on SH-SY5Y cells. (A) MTT assay of SH-SY5Y cells treated with Aβ(1–40)
aggregates after 5 days of incubation with or without antibody fragments at 5:1 molar ratio of Aβ versus B10 or KW1. Molar ratio refers to the
polypeptide chains. Cells treated with buffer were set to 100%. The general cell toxin staurosporine (STS, 2 μM) served as a positive control.
(B,C) MTT-reduction (B) and LDH assay (C) of SH-SY5Y cells treated with Aβ(1–40) incubated for different periods of time with KW1 (blue) or
without (white). SSP-treated cells defined 100% LDH activity. (D) MTT assay of SH-SY5Y cells treated with Aβ(1–40), Aβ(1–42) or Aβ(1–42)arc
peptides incubated in 50 mM HEPES buffer, pH 7.4, 50 mM NaCl at 37°C for 5 days with KW1 (blue) or without (white). n.s.: non-significant,
**: p < 0.01, ***: p < 0.001. Error bars represent standard deviation of n = 6. (E) Corresponding Aβ isoforms with or without KW1 plotted based on
original life span data (Table 1) and MTT reduction in vitro (Figure 6). Please note the overlap of several data points. The strong correlation
between MTT reduction and neurotoxicity in vivo fits with linear regression (R = 0.98).
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In this study we show that conformational targeting is a
suitable approach to probe the process of Aβ aggrega-
tion and its neurotoxic consequences in an intact living
organism, the fruit fly. Previous research already estab-
lished that targeting of Aβ monomers in vivo with an
artificial Affibody binding protein (analogous to theantibody fragments described here) is able to interfere
with Aβ toxicity in vivo [49] and so we sought to extend
this experimental design in the present study to investi-
gate multimeric peptide assemblies of Aβ in a similar
manner. Our results reveal a striking contrast between
the effects of targeting oligomeric and fibrillar assem-
blies of the Aβ peptide in vivo. Whilst the fibril-binding
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toxicity associated with any of the forms of Aβ studied
here, the oligomer-specific KW1 antibody fragment
shows a potent and highly specific effect and alters tox-
icity in the fly model. This observation is consistent with
the view that oligomeric intermediates are more toxic
than mature fibrils.
Unexpectedly, KW1 promotes rather than neutralizes
toxicity. This finding is in sharp contrast to many previous
studies, which report oligomer-binding conformational li-
gands to antagonize the detrimental effects of oligomers
(Figure 5A,B), presumably by preventing their binding to
cellular surfaces or receptors. These previous studies usu-
ally used an experimental set up where the disturbance of
ordered neuronal functions was recorded in response to
preformed toxic oligomers. Thus, addition of an oligomer-
specific binder to this system interfered with this process
and blocked the effects of oligomers on neurons [50-56].
If KW1 is explored under such a set-up, for example by
using LTP measurements as the readout of toxicity, we
find oligomeric activity to be blocked [29], similar to many
other oligomer-specific ligands.
This test system, however, does not capture the possi-
bility that an oligomer-binder can affect the peptide dur-
ing aggregates, which is physiologically relevant as KW1
is present in the fly together with Aβ(1–40) peptide for
prolonged periods of time. If we remodel this situation
in vitro by allowing Aβ(1–40) peptide to aggregate in the
presence of KW1, we obtain a result that is now fully
consistent with the fly data and demonstrates an in-
creased Aβ activity in both LTP (Figure 5H) and MTT
assays (Figure 6A). The mechanism underlying these
effects appears therefore to involve interference by
the oligomer-specific binder KW1 with the process of
the assembly of Aβ peptides into amyloid structures
(Figure 5C). This effect could result from a variety of
processes, such as the suppression of the late stages of
the aggregation reaction through binding to early inter-
mediates or interaction with late-stage intermediates
such that non-fibrillar Aβ assemblies prevail (Figure 5E).
Indeed, the effects of KW1 are also associated with an
altered structure of the Aβ peptide that is evident
from TEM (Figure 5E) and ANS binding experiments
(Figure 5F). Moreover, it appears that the Aβ(1–40)
peptide only becomes toxic under certain conditions,
such as is observed here in the presence of KW1 as a
cofactor.
Another highly remarkable finding from our fly studies is
that KW1 selectively affected Aβ(1–40)-expressing flies and
mirrors the in vitro observation that KW1 preferen-
tially interacts with Aβ(1–40)-derived oligomers compared
with Aβ(1–42) or Aβ(1–42)-arc-derived intermediates
(Additional file 1: Figure S5A, D, G). That is, there must be
at least subtle differences in the structure or surface textureof these states and also, as Aβ toxicity is not affected by
KW1 in all fly models, in the mechanisms by which they
form.
These data have significance for the design of Aβ-
modifying therapeutic strategies for the treatment of Alz-
heimer’s disease. First, if Aβ-dependent AD pathology does
not only depend on a single Aβ state, strategies to bind and
to neutralize Aβ peptide more generally or to simultan-
eously prevent formation of multiple peptide assembly
states may be preferable for achieving efficient therapeutic
design rather than targeting a single, though highly toxic,
molecular state. Second, the biological activity of state-
specific binders might be highly context-dependent, as may
not only block the binding of oligomers to their cellular re-
ceptors, but also modulate the peptide self-assembly reac-
tion. Therefore, the biological consequences of a binder are
difficult to predict a priori, and the same protein, KW1, can
either prevent or enhance the neurotoxicity of Aβ(1-40) de-
pending on the time point in the aggregation process at
which it is added. We believe that this effect could be in
particular a problem of approaches that solely aim to target
oligomers in order to antagonize their activity by binding.
In the case of proteins with additional activities, such as
full-blown antibodies with functional Fc-parts, however,
these effects could be overruled as they may alert the
immune system to induce the specific destruction of
the bound ligand. This explains why oligomer-specific
antibodies may be functional in vivo [53,55].
Conclusions
Understanding the kinetics and underlying mechanisms of
Aβ aggregation in the brains or patients suffering from AD,
and the balance of these process with those that facilitate
degradation and clearance of aggregates, is crucial for maxi-
mising the efficacy of therapeutic strategies based on the
modulation of Aβ aggregation. Conformational targeting
with appropriately designed antibody fragments is not only
a way to determine the types of aggregates that are present
in the intact nervous system of a living animal, but also to
analyse the functional effects arising from specific perturba-
tions of the mechanisms of Aβ peptide aggregation in vivo.
By combining these studies with in vitro analysis of the bio-
physical properties of the antibody fragments and their in-
teractions with Aβ, it is possible to provide significant
insights into the molecular basis of the pathogenesis of con-
formational diseases and perhaps to generate successful
strategies, or to detect potential pitfalls, when devising
therapeutic solutions to these devastating diseases.
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